| Delivering Gene Therapy begins with an introduction that ably sets the gene therapy scene. The recent history of M&A activity is dealt with in a concise manner while presenting the key underlying strategic strands. The technical difficulties of gene therapy safety are exposed early on in the report. The problem is one of the delivery of genes in a safe and controlled way that also enables these genes to be regulated. The advantages of viral and non-vector gene delivery systems are thoroughly examined and the report details experience to date that non-viral vectors have shown an inability to deliver workable quantities of genes to host cells. The use of encapsulated transfected cell systems is also included. The regulatory and safety climates for gene therapy are clearly stated. The regulatory concerns and issues concerning gene therapy are, by necessity, rapidly evolving and changing. |
